Loading data
GYRENasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 116.59 m USD | 105.76 m USD | 113.45 m USD | 102.29 m USD | — |
| Cost of revenue | 5.42 m USD | 3.88 m USD | 4.64 m USD | 4.79 m USD | — |
| Gross profit | — | 101.87 m USD | 108.81 m USD | 97.5 m USD | — |
| Research and development expense | 13.7 m USD | 12.02 m USD | 13.78 m USD | — | — |
| Operating profit | 11.49 m USD | 16.16 m USD | -67.23 m USD | 9.2 m USD | -87.89 m USD |
| Profit before tax | 14.44 m USD | 23.22 m USD | -76.97 m USD | 9.41 m USD | -87.93 m USD |
| Income tax expense | 4.56 m USD | 5.32 m USD | 8.52 m USD | 5.1 m USD | — |
| Net income (reported basis) | 9.88 m USD | 17.9 m USD | -85.48 m USD | 4.31 m USD | -87.93 m USD |
| Net income attributable to common shareholders | 5.03 m USD | 12.09 m USD | -92.93 m USD | 2.3 m USD | — |
| Basic earnings per share | 0.06 USD/share | 0.14 USD/share | -1.41 USD/share | 0.04 USD/share | -2.87 USD/share |
| Diluted earnings per share | 0.02 USD/share | 0.05 USD/share | -1.41 USD/share | 0.03 USD/share | -2.87 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.